12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ibrutinib regulatory update

Pharmacyclics disclosed in its 3Q12 earnings that FDA granted Orphan Drug designation for ibrutinib to treat chronic lymphocytic leukemia (CLL). The Bruton's tyrosine kinase (Btk) inhibitor that covalently binds...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >